SIRION Biotech Plans Path for US Market Expansion
Boston, MA & Martinsried, Germany – November 4, 2018 – LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced that Europe’s leading gene therapy engineer of viral vectors, SIRION Biotech GmbH, is now a client of LaVoieHealthScience. LHS provides strategic communications programming and corporate development expertise to SIRION Biotech, helping to connect SIRION Biotech to relevant stakeholders in the U.S. life science ecosystem. This is particularly important as SIRION Biotech plans its expansion into the U.S. market with its new Cambridge, MA site beginning January 2019.
SIRION Biotech has been engaged in research and licensing collaborations with 3 leading US biotechs in the gene therapy field since 2015. The earliest project was assisted by LaVoieHealthScience beginning in 2014, when the Germany based company with deep scientific roots in gene expression was seeking U.S. partnerships with clinical-stage gene therapy companies in order to expedite their R&D efforts. Partnering together, LaVoieHealthScience and SIRION Biotech built its US profile, visibility and outreach efforts.
“Partnering with LaVoieHealthScience helped us unleash our potential as a business to business provider of custom engineered viral vectors for industrial and academic research and development,” said Chief Operating Officer and Executive Director, Dieter Lingelbach. Our planned expansion into the US market will be a strategic imperative for SIRION Biotech and we are delighted to continue working with LaVoieHealthScience as we chart our course forward.”
“We are fortunate to continue working with SIRION Biotech as Europe’s leader in the field on its next stage of growth and continue our successful partnership together, said Donna L. LaVoie, President & CEO of LaVoieHealthScience. Dieter and founder, Chief Technology Officer, Dr. Christian Thirion have great vision to enable gene therapy and gene editing companies become more successful with the right clinical grade vector technology that will scale through manufacturing.”
LaVoieHealthScience provides public relations, investor relations, marketing and digital communications to build recognition and value for health science innovators. The agency has received more than 30 awards during the past seven years in recognition of the work it has done for its industry-leading clients and was recently inducted into the 2018 Inc. 5000 Hall of Fame list of Fastest Growing Private Companies. LaVoieHealthScience represents public and privately-held leaders such as BIO, Carmell Therapeutics, Emmaus Life Sciences, Landos Biopharma, LEO Science & Tech Hub, Life Sciences Corridor, NewLink Genetics, Newron Pharmaceuticals, Origenis GmbH, PathMaker Neurosystems, Scioto Biosciences, SIRION Biotech, Symbiotix Biotherapies, Triumvira Immunologics, XenoTherapeutics, Xontogeny LLC, and other emerging health and science companies. For more information, please visit: https://lavoiehealthscience.com/
About SIRION Biotech GmbH
SIRION Biotech provides custom engineering and manufacturing services of viral vectors for the life sciences and industry. Its unique focus on improving transduction efficiencies and safety make SIRION Biotech a valuable technology partner for gene and cell therapy trials. LentiBOOSTTM transduction reagent is actively used to improve hematopoitec cell transductions in clinical trials. NextGen AAV capsid evolution projects aim to improve tissue targeting and immune escape of capsids to usher in a new generation of therapeutics for international gene therapy companies.
Account Manager, PR and Marketing